PSY Stock Overview
Through its subsidiary, Blossom Analysis, provides a data and insights platform for the psychedelic healthcare industry.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Shortwave Life Sciences Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0045 |
| 52 Week High | UK£0 |
| 52 Week Low | UK£0 |
| Beta | 0 |
| 11 Month Change | -18.18% |
| 3 Month Change | -80.43% |
| 1 Year Change | -85.48% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| PSY | GB Healthcare Services | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.3% | 1.1% |
| 1Y | -85.5% | 27.5% | 6.9% |
Return vs Industry: PSY underperformed the UK Healthcare Services industry which returned 27.5% over the past year.
Return vs Market: PSY underperformed the UK Market which returned 6.9% over the past year.
Price Volatility
| PSY volatility | |
|---|---|
| PSY Average Weekly Movement | 13.4% |
| Healthcare Services Industry Average Movement | 5.7% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: PSY's share price has been volatile over the past 3 months.
Volatility Over Time: PSY's weekly volatility has increased from 7% to 13% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Rivki Stern-Youdkevich | shortwavelifesciences.com |
Shortwave Life Sciences Plc, through its subsidiary, Blossom Analysis, provides a data and insights platform for the psychedelic healthcare industry. It offers a Software as a Service platform for scientific and regulatory data. The company was formerly known as Psych Capital Plc and changed its name to Shortwave Life Sciences Plc in June 2024.
Shortwave Life Sciences Plc Fundamentals Summary
| PSY fundamental statistics | |
|---|---|
| Market cap | UK£1.31m |
| Earnings (TTM) | UK£0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs PSY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSY income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£0 |
| Earnings | UK£0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PSY perform over the long term?
See historical performance and comparison